



National Securities Market Commission  
Markets Directorate General  
C/ Edison núm. 4  
28006 Madrid

Colmenar Viejo (Madrid), April 1, 2019

Pursuant to Article 17 of Regulation (EU) n° 596/2014 on market abuse and Article 226 of the consolidated text of the Spanish Securities Market Act, approved by Royal Legislative Decree 4/2015, of 23 October, we hereby make the following REGULATORY ANNOUNCEMENT:

“Please find attached press release that Pharma Mar, S.A. will distribute to the media today in relation to the acceptance by ASCO (American Society of Clinical Oncology) and selection for oral presentation at its 19th Annual Congress of the abstract titled “Efficacy and safety profile of Lurbinectedin in second-line SCLC patients: results from a phase II single-agent trial””.

**Pharma Mar S.A.**  
**Avda. de los Reyes, 1**  
**P.I. La Mina**  
**28770 Colmenar Viejo**  
**(Madrid) Spain**  
**[www.pharmamar.com](http://www.pharmamar.com)**